Sigma-Aldrich, a US-based Nasdaq-listed life science company, has agreed to license a gene delivery technology from Oxford BioMedica and will pay $5 million for a stake in the spin out from Oxford University.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.